当下的市场竞争中，医美赛道的布局已成诸多国内外头部美妆企业们的一个"必选项"。近日，有一个功效护肤品牌也盯上了医美赛道，入局注射医美！ 7月23日，据全球多品牌美容和健康公司Waldencast Acquisition Corp.(纳斯达克股票代码：WALD；下称：Waldencast)官网信息显示，其已收购专注于增长 的创新美学及医学皮肤科公司Novaestiq Corp.,(下称：Novaestiq)，并获得了Saypha®系列透明质酸(HA)注射凝胶在美国的独家销售权。 △图源：Waldencast官网 未来，该系列产品将将归于Obagi Medical(Waldencast旗下美国专业功效护肤品牌，下称：欧邦琪)旗下，Novaestiq的交易还提供了未来在北美的新型注射 剂管道。 本次交易具体交易条款并未透露，但值得注意的是，这是Waldencast首次切入注射类医美赛道，也意味着欧邦琪从专业护肤领域(预计到2029年市场规模将 至22亿美元，约合人民币157亿元)进一步延展至皮肤填充治疗领域(预计到2029年将至20亿美元，约合人民币143亿元)，会扩大其可覆盖的市场规模。 功效护肤品牌杀入注射医美 ...

Core Insights - Waldencast plc has acquired Novaestiq Corp, enhancing Obagi Medical's product portfolio with scientifically backed injectable products, positioning it as a leader in the health, beauty, and aesthetics convergence [1][2][6] - The acquisition allows Obagi Medical to expand into the U.S. dermal filler market, projected to reach $2 billion by 2029, effectively doubling its addressable market [1][2] - The Saypha line of hyaluronic acid injectable gels is currently undergoing FDA approval and is recognized for its safety and efficacy, supported by a robust clinical program [3][4] Company Strategy - Obagi Medical aims to integrate medical-grade skincare with aesthetic treatments, enhancing patient satisfaction and outcomes through a holistic, science-driven approach [2][5] - The company is focused on becoming the 1 Dermatological Mega Brand, leveraging a strategy that includes dermatological science, breakthrough innovations, and global expansion [5][6] - The acquisition is expected to create new growth opportunities and strengthen Obagi Medical's market position in the fast-evolving beauty and wellness industry [6] Product Details - Saypha products utilize proprietary technology for advanced HA treatments, ensuring natural-looking results and optimal gel characteristics [4] - The portfolio is backed by extensive clinical studies, emphasizing effectiveness across diverse skin types and tones [3][4] - The acquisition provides access to a future pipeline of novel injectables in North America, further diversifying Obagi Medical's offerings [2][3] Transaction Overview - The acquisition involves cash payments, ongoing royalties based on net sales of Saypha products, and contingent issuance of Waldencast class A shares based on FDA approval and revenue milestones [7] - The transaction reflects Waldencast's commitment to building a multi-brand beauty and wellness platform, enhancing operational scale and market responsiveness [8]

Group 1 - The article discusses the author's background as an Equity Analyst and Accountant specializing in restaurant stocks, highlighting expertise in various segments of the restaurant industry, including QSR, fast casual, casual dining, fine dining, and family dining [1] - The company employs advanced analytical models and specialized valuation techniques to provide detailed insights and actionable strategies for investors [1] - The author is also involved in academic and journalistic initiatives, contributing to institutions that promote individual and economic freedom [1] Group 2 - The article does not contain any specific financial data or performance metrics related to the companies mentioned [2][3]

Financial Performance - Q1 2025 - Net Revenue was $65.4 million, a decrease of 4.1% compared to the previous year[23, 102] - Adjusted Gross Profit was $50.0 million, a decrease of 4.0% compared to the previous year[23, 102] - Adjusted EBITDA was $4.4 million, a decrease of 61.5% compared to the previous year[23, 102] - Obagi Medical's Net Revenue increased by 7.1% to $36.2 million, with an Adjusted Gross Profit of $29.7 million and Adjusted EBITDA of $5.9 million[23, 102] - Milk Makeup's Net Revenue decreased by 15.1% to $29.3 million, with an Adjusted Gross Profit of $20.4 million and Adjusted EBITDA of $4.4 million[23, 102] Liquidity - Net Debt was $172.1 million as of March 31, 2025[34] - Cash and Cash Equivalents were $10.8 million as of March 31, 2025[34] - $22.5 million undrawn commitment under revolving credit facility as of April 30, 2025[34] FY 2025 Outlook - The company anticipates mid-teens Net Revenue growth for FY 2025[35] - The company anticipates mid-to-high teens Adjusted EBITDA Margin for FY 2025[35] Milk Makeup - Hydro Grip Gel Skin Tint - The Hydro Grip Gel Skin Tint launch generated $18 million in EMV (Earned Media Value)[50] - The Hydro Grip Gel Skin Tint launch achieved 406 million in reach and 245 million impressions[50, 51]

Financial Data and Key Metrics Changes - The company reported net revenue of $65.4 million, a decline of 4.1% year-over-year [11] - Adjusted gross profit margin remained strong at 76.4%, an increase of 10 basis points year-over-year [11] - Adjusted EBITDA was $4.4 million, reflecting a margin of 6.7% [11] Performance by Business Line - Milk Makeup experienced a revenue decline of 15.1%, but domestic performance was solid, driven by the successful launch of Hydro Grip Gel Skin Tint [12][13] - Obagi Medical achieved net revenue of $36.2 million, increasing 7.1% from the previous year, despite out-of-stock issues [14] Market Data and Key Metrics Changes - Milk Makeup's U.S. retail sales showed high single-digit growth, particularly due to the launch into Ulta Beauty [12][17] - Obagi Medical's growth was tempered by supply chain issues, but the brand remains the fastest-growing top 10 professional skincare brand [36] Company Strategy and Development Direction - The company aims to strengthen its supply chain and improve flexibility to meet increasing demand [9][20] - Focus on expanding digital channels and retail footprint, with Milk Makeup's entry into Ulta Beauty being a significant step [10][21] - The company is committed to innovation and expanding into new categories while maintaining a disciplined approach to distribution [30][66] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the beauty market and macroeconomic environment but expressed confidence in achieving annual growth and profitability goals [6][7] - The company expects net revenue growth in the mid-teens and adjusted EBITDA margin in the mid to high teens for the full year [27] Other Important Information - The company is actively addressing supply chain disruptions and has implemented strategic changes to enhance operational efficiency [15][18] - Cash position at the end of Q1 was $10.8 million, with net debt totaling $172.1 million [24][25] Q&A Session Summary Question: Can you expand on the supply chain restructuring for Obagi? - Management indicated that they are working on improving the flexibility and responsiveness of the supply chain to better meet demand [45][46] Question: What is driving the slowdown in the physician channel? - Management clarified that there is no significant slowdown in the physician channel, attributing the decline to less favorable comparisons with the previous year [49][50] Question: Can you provide insights on sell-through trends for Obagi and Milk? - Management noted that Milk Makeup's U.S. retail sales were strong, while Obagi operates on a sell-through basis with no significant discrepancies [54][56] Question: What are the expectations for SG&A as sales grow? - Management expects SG&A to grow in absolute terms but aims for operational leverage, keeping it relatively flat as a percentage of sales [73][74] Question: How is the company addressing tariff impacts? - Management stated that the impact of tariffs is manageable, with low exposure to China, and potential pricing actions are being evaluated [69][71]

Financial Data and Key Metrics Changes - The company reported net revenue of $65.4 million, a decline of 4.1% year-over-year [10] - Adjusted gross profit margin remained strong at 76.4%, an increase of 10 basis points year-over-year [10] - Adjusted EBITDA was $4.4 million, reflecting a margin of 6.7% [10] Business Line Data and Key Metrics Changes - Milk Makeup experienced a revenue decline of 15.1%, but domestic performance was solid, driven by the successful launch of Hydro Grip Gel Skin Tint [11][12] - Obagi Medical achieved net revenue of $36.2 million, increasing 7.1% from the previous year, despite out-of-stock issues [13] Market Data and Key Metrics Changes - The company noted strong growth in attractive channels, including professional, specialty, retail, and online, with expectations for continued momentum [9] - Milk Makeup's U.S. retail sales showed high single-digit growth, particularly due to the launch at Ulta [12][16] Company Strategy and Development Direction - The company is focused on strengthening its supply chain and achieving cost efficiency while enhancing flexibility to meet demand [7][19] - The strategic growth initiatives include expanding Milk Makeup and Obagi Medical brands, driving innovation, and increasing community engagement [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing key drivers such as breakthrough innovation, digital channel expansion, and improved product availability [19][20] - The company remains cautious about the macroeconomic environment, anticipating some pressure from softer consumer sentiment and spending [21] Other Important Information - The company has a cash position of $10.8 million and an additional $22.5 million available on its revolving credit facility [23] - Net debt increased to $172.1 million, primarily due to refinancing costs [24] Q&A Session Summary Question: Can you expand on the supply chain restructuring for Obagi? - Management indicated that the supply chain needs to be more responsive and flexible, with ongoing efforts to streamline operations [42][44] Question: What is driving the slowdown in the physician channel? - Management clarified that the slowdown is not due to fewer visits but rather a lack of tailwinds from the previous year's Amazon business conversion [47][49] Question: Can you provide insights on sell-through trends for Obagi and Milk? - Management noted a significant difference between sell-in and sell-through for Milk, with high single-digit retail sales growth, while Obagi's model is based on sell-through [52][54] Question: What is the expected impact of tariffs on costs? - Management stated that even with potential tariff increases, the impact is manageable due to low exposure to China, with possible low to mid-single-digit price increases being evaluated [64][66] Question: How is SG&A expected to change with sales growth? - Management expects SG&A to grow in absolute terms but with substantial operational leverage, keeping it flattish as a percentage of sales [68][70] Question: What are the marketing investment strategies moving forward? - Management plans to increase investments in top-of-funnel advertising for Milk and expand consumer outreach for Obagi, focusing on long-term competitive advantage [74][75]

Financial Performance - Q1 2025 net revenue was $65.4 million, representing a 4.1% decline from Q1 2024 [4][10] - Adjusted gross margin improved to 76.4%, an increase of 10 basis points year-over-year [5][10] - Adjusted EBITDA for Q1 2025 was $4.4 million, or 6.7% of net revenue, reflecting a significant decline of 61.5% compared to Q1 2024 [6][10] Brand Performance - Milk Makeup's net revenue decreased by 15.1% to $29.3 million, impacted by the previous year's successful product launch and inventory reductions [12][13] - Obagi Medical achieved net revenue of $36.2 million, up 7.1% from $33.8 million in Q1 2024, driven by strong direct-to-consumer sales [13][10] Strategic Initiatives - The company is increasing marketing investments by high teens percentage to build brand equity and support long-term growth objectives [3][5] - Milk Makeup's entry into Ulta Beauty and the launch of Hydro Grip Gel Tint are expected to drive future sales growth [3][12] Liquidity and Debt - Waldencast secured a new $205 million five-year credit facility, enhancing financial flexibility and extending debt maturity to March 2030 [7][8] - As of March 31, 2025, the company held $10.8 million in cash and cash equivalents and had a net debt of $172.1 million [8][10] Outlook - The company aims for mid-teens net revenue growth and an adjusted EBITDA margin in the mid-to-high teens for fiscal 2025 [14][15]

Core Points - Waldencast plc is set to release its First Quarter Fiscal 2025 results on May 13, 2025, after the U.S. market closes [1] - A conference call to discuss these results will take place on May 14, 2025, at 8:30 am ET, with participation details provided for investors and analysts [2] Company Overview - Waldencast aims to establish a global best-in-class beauty and wellness operating platform by developing, acquiring, and scaling purpose-driven brands [3] - The company's brand-led business model focuses on customer proximity, business agility, and market responsiveness while preserving each brand's unique identity [3] - The initial step towards this vision involved the business combination with Obagi Medical and Milk Makeup, allowing brands to leverage operational scale and expertise in managing global beauty brands [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

DISCLAIMER Cautionary Statement Regarding Forward-Looking Statements All statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: Waldencast's outlook and guidance for 2025; our ability to deliver financial results in line with expectations; expectations regarding sales, earnings or other future financial performance ...